#3 - Amgen (NASDAQ:AMGN)
Amgen Inc. (NASDAQ: AMGN) is best known to investors and consumers for its anti-inflammatory drug, Enbrel. In its most recent earnings report, Amgen cited a 15% year-over-year decrease in Enbrel sales driven by a decrease in selling price. However, in addition to inflammation, the company’s pipeline is diversified among general medicine, oncology, and rare diseases.
One of the company’s pipeline candidates is MariTide. Like the offerings from Novo Nordisk and Eli Lilly, MariTide activates the GLP-1 hormone receptor to regulate appetite. However, unlike those drugs, MariTide blocks the GIP receptor, which is an appetite suppressant. Phase 1 trials have shown that, at its highest dose, patients lowered their body weight by 14.5% in 85 days.
An added benefit to MariTide is that patients may only need to take the injection once a month, or even less frequently, and still maintain the benefits. On the other hand, it could take the company years to get MariTide to market and there is the possibility of failure.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More - Current Price
- $282.87
- Consensus Rating
- Hold
- Ratings Breakdown
- 12 Buy Ratings, 13 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $323.05 (14.2% Upside)
